The Designer D-dimer Deep Vein Thrombosis Diagnosis (4D) Study
- Conditions
- Suspected Deep Vein Thrombosis
- Registration Number
- NCT02038530
- Lead Sponsor
- McMaster University
- Brief Summary
This is a cohort study that will assess a new diagnostic management strategy for suspected Deep Vein Thrombosis in outpatients.The new diagnostic strategy is designed to reduce the use of ultrasound testing on the day of presentation, and reduce repeat ultrasound testing a week after an initial normal test.
- Detailed Description
This is a prospective, multicentre, cohort study that will assess a new diagnostic management strategy for suspected Deep Vein Thrombosis in outpatients. The new diagnostic strategy is designed to reduce the use of ultrasound testing on the day of presentation, and reduce repeat ultrasound testing a week after an initial normal test. Less ultrasound testing will be performed because: i) more patients will have deep vein thrombosis excluded by combinations of Clinical Pretest Probability and D-dimer results on the day of presentation; and, ii) in those who still need an ultrasound, a repeat ultrasound a week after a normal result will only be performed if the D-dimer result is markedly abnormal at initial presentation. The safety of this management strategy will be established by demonstrating a very low rate of proximal Deep Vein Thrombosis or Pulmonary Embolism during 90 days follow-up in patients who had anticoagulant therapy withheld in response to negative diagnostic testing. Diagnostic test utilization will be assessed. All clinical outcomes will be adjudicated by a central independent adjudication committee that will be blind to initial D-dimer measurements and patient management.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1513
- Consecutive outpatients (i.e. non-hospitalized patients) with clinically suspected Deep Vein Thrombosis.
- Age less than 18 years.
- Treated with full-dose anticoagulation for ≥ 24 hours before D-dimer was measured.
- D-dimer level known before Clinical Pretest Probability documented.
- Ultrasound of the leg performed before Clinical Pretest Probability was documented
- Ultrasound was or will be performed in a patient with low Clinical Pretest Probability and a d-dimer <1000(or equivalent), or with Moderate Clinical Pretest Probability and a D-dimer <500 (or equivalent) (e.g. suspected bleeding).
- Ongoing need for anticoagulant therapy.
- Suspected Pulmonary Embolism.
- Superficial venous thrombosis that requires, or may require, anticoagulant therapy.
- Life expectancy less than 3 months.
- Previously confirmed episode of Deep Vein Thrombosis.
- Geographic inaccessibility which precludes follow-up.
- Known pregnancy.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Confirmed symptomatic proximal Deep Vein Thrombosis within 90 days The primary outcome is confirmed symptomatic proximal Deep Vein Thrombosis (including involvement of the calf vein trifurcation but not isolated more distal Deep Vein Thrombosis; or pulmonary embolism (not including isolated sub-segmental abnormalities on Computed Tomography Pulmonary Angiogram; within 90 days (± 7 days for follow-up assessment) that is not diagnosed by scheduled diagnostic testing (includes events that occur between initial and scheduled follow-up proximal ultrasound examinations).
- Secondary Outcome Measures
Name Time Method Clinical Pretest Probability/ D-dimer/ Compression Ultrasound subgroups within 90 days The primary outcome in the following subgroups:
* Low Clinical Pretest Probability and D-dimer \<1000 ug/L
* Moderate Clinical Pretest Probability and D-dimer \<500 ug/L
* Moderate Clinical Pretest Probability and D-dimer 500 -999 ug/L
* High Clinical Pretest Probability and D-dimer \<500 ug/L
* Low Clinical Pretest Probability and D-dimer 1000-2999 ug/L and negative initial ultrasound
* Moderate Clinical Pretest Probability and D-dimer 1000-2999 ug/L and negative initial ultrasound
* High Clinical Pretest Probability and D-dimer 500-1499 ug/L and negative initial ultrasoundDeath within 90 days Death within 90 days (± 7 days for follow-up assessment).
Trial Locations
- Locations (10)
Nova Scotia Cancer Centre
🇨🇦Halifax, Nova Scotia, Canada
Hamilton Health Sciences - McMaster
🇨🇦Hamilton, Ontario, Canada
St. Joseph's Healthcare
🇨🇦Hamilton, Ontario, Canada
University of Alberta Hospital
🇨🇦Edmonton, Alberta, Canada
Juravinski Cancer Hospital
🇨🇦Hamilton, Ontario, Canada
The Ottawa Hospital Regional Centre
🇨🇦Ottawa, Ontario, Canada
Hamilton Health Sciences - Hamilton General
🇨🇦Hamilton, Ontario, Canada
London Health Sciences Centre
🇨🇦London, Ontario, Canada
The Jewish General Hospital
🇨🇦Montreal, Quebec, Canada
Centre Hospitalier Universitaire de Sherbrooke
🇨🇦Sherbrooke, Quebec, Canada